InsiderLens
All transactionsBrowse millions of insider transactions
Top buysLargest insider purchases
Top sellsLargest insider sales
Cluster activityMultiple insiders trading together
All companiesBrowse all 22,000+ companies
ScreenerFilter by sector, country, activity
By countryBrowse by market
All InsidersBrowse all 240,000+ Insiders
Most activeInsiders with the most trades
Best performersHighest returns on insider buys
Alerts

Global search

Find a company or insider, or run a shortcut.

InsiderLens

Track insider trading activity, analyze financial data, and monitor insider transactions across global markets.

Transactions

  • Top buys
  • Top sells
  • Companies
  • Insiders
  • Screener

Resources

  • API
  • Blog
  • Help center
  • Methodology

Company

  • About
  • Contact
  • Privacy policy
  • Terms of service
  • Cookie policy

Data sources: SEC EDGAR (US) · AMF / BDIF (FR) · BaFin (DE) · FCA (GB) · FSMA (BE) · AFM (NL) · CNMV (ES) · SIX (CH) · FI (SE) · Oslo Børs (NO) · Nasdaq Nordic & Baltic · and 20+ other European regulators.

The information provided on InsiderLens is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Insider transaction data is sourced from public regulatory filings. Past insider transactions do not guarantee future performance. Always consult a qualified financial advisor before making investment decisions.

© 2026 InsiderLens

  1. Home
  2. /
  3. Insiders
  4. /
  5. Lacey David L.

Lacey David L.

BalancedInformative
BoardArcus Biosciences, Inc.·Atreca, Inc.·Nurix Therapeutics, Inc.·Unity Biotechnology, Inc.CIK 0001734422
23 transactions·4 companies·Last Jun 10, 2025
$00 buys
$00 sells
50%/50%38K shares held ≈ $1.0M
BOARD MEMBERatArcus Biosciences, Inc.RCUS

Last filing: Apr 2026

BOARD MEMBERatAtreca, Inc.BCEL

Last filing: Apr 2026

BOARD MEMBERatNurix Therapeutics, Inc.NRIX

Last filing: Apr 2026

+ 1 more company

Also at Arcus Biosciences, Inc.

RJ
ROSEN TERRY J
CEO68 tx
GC
Goeltz II Robert C.
CFO61 tx
JJ
Jarrett Jennifer
C SUITE117 tx
AA
Azoy Alexander
C SUITE37 tx
GW
Grossman William
C SUITE28 tx

Insider transactions by Lacey David L.

23 transactions — - in purchases, - in sales

DateViaCompanyTypeSharesValue
Jun 10, 25DirectRCUSArcus Biosciences, Inc.Grant38 300-
Jun 10, 25DirectRCUSArcus Biosciences, Inc.Grant13 300-
May 19, 25DirectNRIXNurix Therapeutics, Inc.Grant25 000-
Jan 23, 25DirectRCUSArcus Biosciences, Inc.Grant5 000-
Jun 6, 24DirectRCUSArcus Biosciences, Inc.Grant24 000-
Jun 6, 24DirectRCUSArcus Biosciences, Inc.Grant8 400-
May 20, 24DirectNRIXNurix Therapeutics, Inc.Grant25 000-
Jun 15, 23DirectRCUSArcus Biosciences, Inc.Grant19 500-
Jun 15, 23DirectRCUSArcus Biosciences, Inc.Grant6 800-
Jun 13, 23DirectBCELAtreca, Inc.Grant12 000-
May 4, 23DirectNRIXNurix Therapeutics, Inc.Grant25 000-
Jun 14, 22DirectRCUSArcus Biosciences, Inc.Grant16 800-
Jun 14, 22DirectRCUSArcus Biosciences, Inc.Grant4 100-
Jun 8, 22DirectBCELAtreca, Inc.Grant12 000-
May 5, 22DirectNRIXNurix Therapeutics, Inc.Grant17 500-
Jun 9, 21DirectBCELAtreca, Inc.Grant12 000-
Jun 3, 21DirectRCUSArcus Biosciences, Inc.Grant14 100-
Jun 3, 21DirectRCUSArcus Biosciences, Inc.Grant3 000-
May 6, 21DirectNRIXNurix Therapeutics, Inc.Grant17 500-
Jun 18, 20DirectUBXUnity Biotechnology, Inc.Grant25 000-
Jun 10, 20DirectBCELAtreca, Inc.Grant12 000-
May 21, 20DirectRCUSArcus Biosciences, Inc.Grant50 000-
Jun 20, 19DirectUBXUnity Biotechnology, Inc.Grant25 000-
Direct = personal transaction
Via entity / trust / associate

Frequently asked questions about Lacey David L.

What are Lacey David L.'s recent insider transactions?

Lacey David L. has filed 23 insider transactions across 4 companies, totaling $0 in purchases and $0 in sales. The most recent filing was on June 10, 2025.

Is Lacey David L. a net buyer or seller of shares?

Based on regulatory disclosures, Lacey David L. is a net seller with 0 purchases and 0 sales on record.

Data sourced from public regulatory filings (SEC EDGAR, AMF, BaFin). This information is provided for educational purposes and does not constitute investment advice, a recommendation, or a solicitation to buy or sell securities.

Updated June 10, 2025·Full disclaimer